Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132338 | PMC |
| http://dx.doi.org/10.4103/0971-4065.82377 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ceftriaxone-induced hemolytic anemia managed successfully in a 54-year-old woman: a case report and literature review.
Front Pharmacol
January 2025
Department of Emergency, Peking University People's Hospital, Beijing, China.
Ceftriaxone is widely used in clinical practice for its efficacy against infections. However, its increasing association with life-threatening immune hemolytic reactions urge clinicians to enhance recognition and maintain sharp vigilance. This report details a rare and severe case of ceftriaxone-induced hemolytic anemia (CIHA), hemodynamic instability and hemolytic crisis in a 54-year-old woman after intravenous infusion of ceftriaxone following a respiratory infection.
View Article and Find Full Text PDFPrevalence of direct antiglobulin test positive in whole blood donors: Study at a tertiary blood center Northern India.
Asian J Transfus Sci
December 2024
Department of Transfusion Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.
Background: The direct antiglobulin test (DAT) detects red blood cell (RBC) sensitivity to complement or IgG . The clinical disorders of hemolytic disease of the newborn, hemolytic transfusion reaction, and autoimmune and drug-induced hemolytic anemia are some examples of those that can cause coating of RBCs with antibodies or complement autoimmune hemolytic anemia (AIHA). Rarely, DAT is positive in nonimmune-mediated hemolytic anemias as well.
View Article and Find Full Text PDFUnraveling the complexity: Case reports of drug-induced hemolytic anemia due to ceftriaxone.
Asian J Transfus Sci
August 2024
Department of Immunohematology and Transfusion Medicine, Santokba Durlabhji Memorial Hospital, Jaipur, Rajasthan, India.
Drug-induced hemolytic anemia (DIHA) is a rare but significant condition characterized by the premature destruction of red blood cells (RBCs) triggered by certain medications. Ceftriaxone, a commonly used antibiotic, has been linked to DIHA, presenting diagnostic challenges due to its diverse clinical manifestations. This study examines three cases of DIHA caused by ceftriaxone therapy at our center.
View Article and Find Full Text PDFArtesunate-induced anaemia: A case report of a pharmacological complication to consider.
Parasitol Int
January 2025
Infectious Diseases Division, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Article Synopsis
- A 52-year-old man was admitted to the ICU in septic shock from severe malaria after traveling to Ghana, with a high parasitaemia index of 50%.
- He was treated with intravenous artesunate and dihydroartemisinin plus piperaquine, leading to rapid clinical improvement and a 0% parasitaemia level within 72 hours, but developed severe anaemia with hemoglobin dropping to 5.6 g/dL.
- The anaemia was diagnosed as post-artesunate haemolytic anaemia (PDAH) due to high parasitaemia and treatment, treated with oral steroids, highlighting the need for awareness of PDAH in severe malaria cases for effective recovery.
Red blood cell agglutination caused by ceftriaxone and its effect on erythrocyte parameters: a case report.
Biochem Med (Zagreb)
February 2025
Department of Medical Biochemistry and Hematology, Children's Hospital Zagreb, Zagreb, Croatia.
Ceftriaxone, a widely used antibiotic, is one of the most common drugs to cause drug-induced immune hemolytic anemia. In this report, we describe the effect of ceftriaxone on red blood cell parameters (low red blood cell count, low hematocrit, and high erythrocyte index values) in two pediatric patients without clinical symptoms of hemolytic anemia. Although automated hematology analyzers have helped to detect incorrect results, a peripheral blood smear examination was necessary for recognizing the erythrocyte agglutinins caused by ceftriaxone.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!